Validation of anti-aging drugs by treating age-related diseases.

111Citations
Citations of this article
107Readers
Mendeley users who have this article in their library.

Abstract

Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.

Cite

CITATION STYLE

APA

Blagosklonny, M. V. (2009, March). Validation of anti-aging drugs by treating age-related diseases. Aging. https://doi.org/10.18632/aging.100034

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free